Velomedix, Inc., a Menlo Park, California-based development stage medical device company advancing the clinical field of Therapeutic Hypothermia, has closed $10.2m in Series B funding.
The company intends to use the funding to initiate a post-CE Mark trial in support of EU commercialization and obtain U.S. Food and Drug Administration approval for a clinical study in the United States.
Led by newly oppinted Chief Executive Officer Jeffrey (Jeff) Gold and Vice-President of Operations Michael Moore, Velomedix was created to realize the clinical potential of mild Therapeutic Hypothermia in benefiting patients suffering from ischemic and reperfusion injury effects of cardiac arrest, heart attack, stroke, and trauma brain injury.
The company is also led by Griff Tully, MD, Vice-President & Chief Medical Officer.
FinSMEs
08/02/2012